Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 27;11(8):828–840. doi: 10.1093/stcltm/szac041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Non-dose-dependent effects of WJ-MSC EVs on lung cytokine concentration. Multiplex array demonstrate similar reduction in the lung concentration of (A) IL-1β, IL-1α, IL-6, TNF-α, MIP-1 α, MCP-1, and leptin concentration in 2-week-old hyperoxia (HYP) exposed rats treated with IT low dose (LD), medium dose (MD), and high dose (HD) WJ-MSC EV. In contrast, lung VEGF concentration was increased by all doses of WJ-MSC EV. Data are presented as mean ± SEM; N = 4–5/group. *P < .05, room air (RA) placebo (PL) vs. HYP PL or HYP PL vs. HYP WJ-MSC EV LD, MD, or HD. (B) Treatment of hyperoxia-exposed human pulmonary microvascular endothelial cells with WJ-MSC EVs 10 or 20 ug/mL increased capillary tube formation and (C) this was non-dose dependent. All experiments were performed in quadruplicate. *P < .05, normoxia control vs. hyperoxia control or hyperoxia control vs. hyperoxia WJ-MSC EV 10 or 20 ng/mL.